Orexo AB (publ) (LON:0H19)

London flag London · Delayed Price · Currency is GBP · Price in SEK
14.61
-0.37 (-2.47%)
At close: May 12, 2025
-34.92%
Market Cap 40.05M
Revenue (ttm) 46.03M
Net Income (ttm) -16.19M
Shares Out n/a
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 139
Open n/a
Previous Close 14.98
Day's Range n/a
52-Week Range 1.02 - 1.63
Beta 0.66
RSI 50.03
Earnings Date May 6, 2025

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 110
Stock Exchange London Stock Exchange
Ticker Symbol 0H19
Full Company Profile

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.